Date: May 13, 2013 Source: Fierce Biotech IT (
click here to go to the source)
Instem has bought a ticket to play a larger role in the market for early-stage clinical trials. The provider of IT solutions has acquired Logos Technologies, which provides electronic data-capture (EDC) software for pharma, biotech and CRO companies.
As drug developers abandon paper for pixels, Logos' "Alphadas" software products include a number of tools such as EDC, electronic patient reporting (ePRO), and CTMS that target the early stage market. The mid- and late-stage trials market for EDC is dominated by Oracle ($ORCL)/Phase Forward, Medidata Solutions ($MDSO), Perceptive Informatics/Parexel and others. Yet Instem appears to see an opening for growth in the early-stage segment of the market.
Instem and London-based Logos did not reveal financial details of the acquisition deal in a press release.
The Biotech Primer: An insider's guide to the science driving the biotech and pharma industries
This 200-page book takes an in-depth look at the biotech industry and the science that drives it. Although the industry itself is constantly changing, these fundamental concepts upon which it is built will remain important for years to come - and decision-makers who understand these fundamentals will be better able to evaluate and predict new trends. Click here to buy today!
Logos, which has employees in the U.S. and U.K., has designed its software to reduce the time required for clinical trials. Trials have been notoriously costly and time-consuming, and IT companies have looked to give drug developers advantages with their software. Pharma companies have been using EDC software in general for more than a decade, and now the race is on to offer enhancements and complementary software tools to drive efficiency in trials.
"We are delighted that the talented team at Logos will be joining the Instem group," Instem's CEO Phil Reason said in a statement," and we look forward to working together to provide valuable automation tools that will enable our clients to bring new products to market quickly and cost effectively.
With the buyout deal from Instem, which is listed as ($INS) on the London exchange, plans call for Logos to offer a software-as-a-service option for its products, hoping to appeal to early-stage units with support of its software over the web.
